At Roche you can show up as yourself, embraced for the unique qualities you bring. Our culture encourages personal expression, open dialogue, and genuine connections, where you are valued, accepted and respected for who you are,
Full Stack Developer (m/w/d) Zu der Datalynx Gruppe gehören die Unternehmen Datalynx AG, Primetrack AG und skillcloud AG. Sie erbringen IT Dienstleistungen rund um Digitale Lösungen, Quality Management, Helpdesk/Support und Workforce Solutions. m Bereich Digitale Lösungen
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Idorsia Ltd is reaching out for more – We have more ideas, we see more opportunities and we want to help more patients. In order to achieve this, we will develop Idorsia into a leading biopharmaceutical
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)
Vacancy Lab Compute Analyst Location Basel - Switzerland Hours Full-time Lab Compute Analyst - Basel Role Overview: A Zifo Lab Compute Analyst provides both consulting, analytical and technical laboratory services, including multivendor instrument, information technology as
Job description Help our clients to find vulnerabilities before cyber-criminals do Do you enjoy the thrill of hacking into systems on online training platforms or bug bounty programs? Would you like to turn your passion into
Für meinen Auftraggeber, ein global agierendes, mittelständisches und stetig wachsendes Unternehmen, das als erfolgreicher Anbieter von maßgeschneiderten Materialflusslösungen für verschiedene Branchen und Kunden Microsoft Dynamics NAV als ERP-System einsetzt und sich als Produktionsbetrieb mit einem Produktsortiment
Revolution Medicines is a late-stage clinical oncology company developing novel targeted therapies for patients with RAS-addicted cancers. The company’s R&D pipeline comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins. The company’s RAS(ON)